COGENT BIOSC.INC.DL-,001 Logo
US19240Q2012
A2QJAY
COGT

COGENT BIOSC.INC.DL-,001

Chargement des cours...

Prévisions

L'objectif de cours moyen des analystes est de 46,10 € (+82,00 %). La médiane est de 47,31 € (+86,77 %).

Acheter
  10
Conserver
  2
Vendre
  0

Discussions dans la communauté

Il n'y a pas encore de discussion sur cet actif.

Lancer une discussion

  • Cogent Bioscience files FDA application for bezuclastinib to treat advanced systemic mastocytosis

    Cogent Bioscience filed a New Drug Application with the U.S. FDA for bezuclastinib on June 30, supported by encouraging results from the APEX pivotal trial. CEO Andrew Robbins said the company is engaging closely with the FDA on three submissions and expects initial approvals by the end of 2026. The company is also advancing a JAK2 V617F mutation‑specific inhibitor with plans to file an IND in 2026. Bezuclastinib is a selective tyrosine kinase inhibitor targeting KIT mutations and is approaching Phase 3 development. » Plus sur finance.yahoo.com


  • Cogent Biosciences presents preclinical data showing mutant‑selective JAK2 inhibitor CGT1145 with >100‑fold selectivity

    Cogent Biosciences reported early preclinical results for CGT1145 showing more than 100‑fold selectivity for JAK2 V617F over wild‑type JAK2 and JAK1/3, suggesting reduced off‑target effects that can cause low blood counts. The compound demonstrated strong oral bioavailability, consistent pharmacology across models, and potential to eradicate disease‑driving cells and support molecular remission in JAK2 V617F‑driven blood cancers. Cogent said it remains on track to file an Investigational New Drug application with the FDA later this year. » Plus sur finance.yahoo.com


  • Cogent Biosciences projects >$3bn peak sales for bezuclastinib amid near-term regulatory catalysts

    Cogent Biosciences is advancing bezuclastinib, a selective KIT D816V inhibitor, with NDAs accepted for indolent systemic mastocytosis (PDUFA Dec 2026) and imminent submission for advanced disease, and an RTOR NDA for second-line GIST where trials showed improved PFS versus standard care. The company also develops additional oncology assets (pan-KRAS, JAK2, FGFR2/3) that broaden its commercial optionality. Analysts and investors view Cogent as an attractive M&A target given de-risked data, multiple near-term catalysts and projected multibillion-dollar sales, though safety and competition remain risks. » Plus sur finance.yahoo.com


  • Kynam Capital trims $48M position in Cogent Biosciences but leaves it as top holding

    Kynam Capital Management sold 1,720,949 shares of Cogent Biosciences in Q4, an estimated $48.38 million reduction based on quarterly average pricing, while the position still represents about 14% of reported AUM and remains the fund's largest holding. Cogent shares have surged roughly 360% over the past year and trade at $33.38 as of Friday. Recent catalysts include FDA acceptance of bezuclastinib’s filing with a December 30 target action date and year-end cash of $900.8 million, supporting operations into 2028. The sale appears to be a risk-management trim rather than a shift in conviction according to the filing and portfolio context. » Plus sur finance.yahoo.com


  • Cogent Biosciences advances bezuclastinib NDAs after positive pivotal trials and secures strong cash runway

    Cogent Biosciences reported 2025 regulatory momentum for lead candidate bezuclastinib following three positive pivotal trials and submitted an NDA for Non-Advanced Systemic Mastocytosis in December 2025, with an Advanced Systemic Mastocytosis NDA expected in H1 2026. The company is also completing a rolling NDA for second-line GIST under the FDA Real-Time Oncology Review, supported by PEAK trial data showing median progression-free survival of 16.5 months. Cogent maintains a robust pipeline including CGT1145 and CGT1815 and ended 2025 with $900.8 million in cash and marketable securities, funded partly by a $546.8 million offering and projected to finance operations into 2028. » Plus sur finance.yahoo.com

Données financières de l'entreprise

Au dernier trimestre, COGENT BIOSC.INC.DL-,001 a réalisé un chiffre d'affaires de 0 € et un bénéfice net de -98,37 M €
(EUR) septembre 2026
YoY
Chiffre d'affaires 0 -
Bénéfice brut 0 -
Bénéfice net -98,37 M 42,65 %
EBITDA -96,77 M 44,99 %

Données fondamentales

Indicateur Valeur
Capitalisation boursière
4,52 Md €
Nombre d'actions
173,99 M
Plus haut/bas sur 52 semaines
39,79 € - 25,23 €
Dividendes Non
Bêta
0,34
Ratio P/E
-12,31
Ratio PEG
-2,02
Ratio P/B
9,58
Ratio P/S
0,00

Profil de l'entreprise

Cogent Biosciences, Inc., une société de biotechnologie, se consacre au développement de thérapies de précision pour les maladies à déterminisme génétique défini. Son principal candidat-médicament en développement comprend le CGT9486, un inhibiteur sélectif de tyrosine kinase conçu pour inhiber la mutation KIT D816V, à l'origine de la mastocytose systémique, ainsi que d'autres mutations de l'exon 17 du gène KIT, présentes chez des patients atteints de tumeurs stromales gastro-intestinales avancées. La société a conclu un accord de licence avec Plexxikon Inc. pour la recherche, le développement et la commercialisation du bezuclastinib. La société était auparavant connue sous le nom d'Unum Therapeutics Inc. et a changé sa dénomination en Cogent Biosciences, Inc. en octobre 2020. Cogent Biosciences, Inc. a été constituée en 2014 et son siège social se trouve à Cambridge, dans le Massachusetts.

Nom
COGENT BIOSC.INC.DL-,001
PDG
Andrew R. Robbins
Siège social Waltham, ma
États-Unis
Site web
Secteur
Matériaux
Industrie
Produits chimiques
Introduction en bourse
29/03/2018
Employés 258

Symboles boursiers

Bourse Symbole
NASDAQ
COGT
🍪

Parqet  utilise des cookies. En savoir plus